Xeljanz Eiropas Savienība - latviešu - EMA (European Medicines Agency)

xeljanz

pfizer europe ma eeig - tofacitinibs - artrīts, reimatoīds - imūnsupresanti - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 un 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Lidaprim Forte 800 mg/160 mg apvalkotās tabletes Latvija - latviešu - Zāļu valsts aģentūra

lidaprim forte 800 mg/160 mg apvalkotās tabletes

rokitan gmbh, austria - trimethoprimum, sulfametrolum - apvalkotā tablete - 800 mg/160 mg

Levofolic 50 mg/ml šķīdums injekcijām/infūzijām Latvija - latviešu - Zāļu valsts aģentūra

levofolic 50 mg/ml šķīdums injekcijām/infūzijām

medac gesellschaft für klinische spezialpräparate mbh, germany - levofolīnskābe - Šķīdums injekcijām/infūzijām - 50 mg/ml

Orfarin 3 mg tabletes Latvija - latviešu - Zāļu valsts aģentūra

orfarin 3 mg tabletes

orion corporation, finland - varfarīna nātrija sāls - tablete - 3 mg

Orfarin 5 mg tabletes Latvija - latviešu - Zāļu valsts aģentūra

orfarin 5 mg tabletes

orion corporation, finland - varfarīna nātrija sāls - tablete - 5 mg

Salazopyrin EN 500 mg zarnās šķīstošās tabletes Latvija - latviešu - Zāļu valsts aģentūra

salazopyrin en 500 mg zarnās šķīstošās tabletes

pfizer europe ma eeig, united kingdom - sulfasalazīns - zarnās šķīstošās tabletes - 500 mg

Bactrim 40 mg/8 mg/ml sīrups Latvija - latviešu - Zāļu valsts aģentūra

bactrim 40 mg/8 mg/ml sīrups

eumedica pharmaceuticals gmbh, germany - sulfamethoxazolum, trimethoprimum - sīrups - 40 mg/8 mg/ml

Lanvis 40 mg tabletes Latvija - latviešu - Zāļu valsts aģentūra

lanvis 40 mg tabletes

aspen pharma trading ltd., ireland - tioguanīns - tablete - 40 mg

Omvoh Eiropas Savienība - latviešu - EMA (European Medicines Agency)

omvoh

eli lilly nederland b.v. - mirikizumab - kolīts, čūlas - imūnsupresanti - omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.

Doxorubicin Ebewe 2 mg/ml koncentrāts infūziju šķīduma pagatavošanai Latvija - latviešu - Zāļu valsts aģentūra

doxorubicin ebewe 2 mg/ml koncentrāts infūziju šķīduma pagatavošanai

sandoz d.d., slovenia - doksorubicīna hidrohlorīds - koncentrāts infūziju šķīduma pagatavošanai - 2 mg/ml